By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Metamark Genetics said yesterday that it has signed a research and licensing deal with Janssen Biotech on identifying and validating prognostic markers for cancer.

The firms intend to validate several of Metamark's Prognostic Determinants, which are genes that are believed to play a causal role in promoting tumor progression and metastases. Cambridge, Mass.-based Metamark makes MetamarkDx Prognostic Assays based on the Prognostic Determinants technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.